Who was studied?
A single-ascending-dose trial and a weekly multiple-ascending-dose trial; the latter enrolled people with overweight or obesity without diabetes. The abstract does not state cohort sizes.
- Participants
- First-in-human cohorts
- Duration
- Single exposure / 12 weeks
- Funding
- The United Laboratories; authors include TUL, United Biotechnology and Novo Nordisk affiliations
What did the study find?
The report describes approximately linear pharmacokinetics over 1–6 mg and weight reduction over 12 weeks. Laboratory findings, decreased appetite and gastrointestinal events were the most common adverse effects.
What should you keep in mind?
An early, short study primarily assessing safety and tolerability, not a comparison with Retatrutide. The abstract lists Chinese registry IDs ChiCTR2600116148 and ChiCTR2600123803.
Why it matters
The published paper is an early human reference point. It does not establish a dose conversion or a universal community schedule.
Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study
Published 2026 · PMID 42712041 · DOI 10.1111/dom.71327
Summary by Peptide Lit, checked against the original abstract on October 9, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.